Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Inclusion Criteria

• •Subject is judged by the investigator to be suitable for participation in a 24-week clinical trial involving open-label lurasidone treatment
• •Subject has completed the 6-week treatment period and all required assessments on the final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study D1050236, NCT#008668699.